Holen Sie sich die Stockscreener-App
1.8999
0.00%
0.0299
Schlusskurs vom Vortag:
$1.87
Offen:
$1.89
24-Stunden-Volumen:
12,877
Relative Volume:
0.20
Marktkapitalisierung:
$2.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.98M
KGV:
-0.2167
EPS:
-8.7693
Netto-Cashflow:
$-6.49M
1W Leistung:
+2.19%
1M Leistung:
-34.39%
6M Leistung:
-78.63%
1J Leistung:
-88.84%
1-Tages-Spanne:
$1.87
$1.9763
1-Wochen-Bereich:
$1.54
$2.0438
52-Wochen-Spanne:
$1.54
$30.25
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Firmenname
Adial Pharmaceuticals Inc
Sektor
Branche
Telefon
434-422-9800
Adresse
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
1.90 | 2.08M | 0 | -7.98M | -6.49M | -8.7693 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.28 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.73 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
695.77 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.50 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2018-10-30 | Eingeleitet | Maxim Group | Buy |
| 2018-10-11 | Eingeleitet | Dawson James | Buy |
Adial Pharmaceuticals Inc Aktie (ADIL) Neueste Nachrichten
Tech Rally: Whats the fair value of Adial Pharmaceuticals Inc stockPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Is Adial Pharmaceuticals Inc. stock a smart buy before Fed meetingPortfolio Return Report & High Conviction Investment Ideas - Naître et grandir
Key facts: Adial Pharmaceuticals reports $7.98M annual loss; 2025 results show regulatory progress - TradingView
Adial Pharmaceuticals (ADIL) Enhances Financial Position and Cli - GuruFocus
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update - TradingView
FDA policy shift could give Adial cheaper route for alcohol-use drug - Stock Titan
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - mx.advfn.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Adial Pharmaceuticals signs framework deal with Molteni for Europe By Investing.com - Investing.com Canada
Adial Pharmaceuticals (ADIL) Plans European Expansion for AD04 w - GuruFocus
Adial Pharmaceuticals signs exclusive AD04 collaboration framework with Molteni Farmaceutici for Europe - marketscreener.com
Adial Pharmaceuticals signs framework deal with Molteni for Europe - Investing.com
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization - TipRanks
Adial Pharmaceuticals enters exclusive AD04 Europe framework with Molteni; potential $60M in royalties & milestones - TradingView
Adial (NASDAQ: ADIL) outlines AD04 Europe deal framework with Molteni - Stock Titan
Adial Pharmaceuticals, Inc. Enters into A Collaboration Framework Agreement with Molteni Farmaceutici - marketscreener.com
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Adial Pharmaceuticals (ADIL) to Release Quarterly Earnings on Tuesday - Defense World
Adial Pharmaceuticals, IncWarrant (NQ: ADILW - The Chronicle-Journal
Adial Pharmaceuticals Secures Exchange Listing Amid Regulatory Tailwinds - AD HOC NEWS
ADIL Should I Buy - Intellectia AI
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 87.7% - Defense World
ADIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ARMISTICE CAPITAL, LLC Acquires Shares in Adial Pharmaceuticals Inc - GuruFocus
Key facts: Adial Pharmaceuticals meets Nasdaq bid requirement; advances AD04 to Phase 3 trial - TradingView
Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program - TipRanks
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - Bitget
Adial Pharmaceuticals regains full compliance with Nasdaq listing requirement - marketscreener.com
Adial Regains Nasdaq Compliance as AD04 Advances, Engages in Partnering Talks - TradingView
Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement - TradingView
Adial Pharmaceuticals (ADIL) regains Nasdaq compliance, highlights AD04 Phase 3 path - Stock Titan
Adial Pharmaceuticals eyes single pivotal trial path for AD04 - Investing.com India
Adial Pharmaceuticals eyes single pivotal trial path for AD04 By Investing.com - Investing.com Australia
Adial Pharmaceuticals stock rises on FDA policy shift - Investing.com South Africa
Adial Pharmaceuticals stock rises on FDA policy shift By Investing.com - Investing.com Canada
Adial Pharmaceuticals (ADIL) Sees Potential in FDA's New Approva - GuruFocus
Portfolio Shifts: Can Adial Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Volume & Consistent Profit Alerts - baoquankhu1.vn
ADIL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Adial Pharmaceuticals to Present at Healthcare Conference - National Today
Alcohol Use Disorder Pipeline 2026: Latest FDA Approvals, Clinical Trials, And Emerging Therapies Assessment By Delveinsight Alkermes, Teva Pharma, Biocorrx, Inc., Adial Pharma, ADDEX THERAPEUTICS - Mena FN
Alcohol Use Disorder Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Alkermes, Teva Pharma, BioCorRx, Inc., Adial Pharma, ADDEX THERAPEUTICS - Barchart.com
Fund Flows: Whats the beta of Adial Pharmaceuticals Inc stockCPI Data & Technical Entry and Exit Alerts - baoquankhu1.vn
Armistice Capital, Steven Boyd report 9.99% stake in ADIL (NASDAQ: ADIL) - Stock Titan
Adial Pharmaceuticals to Present at Oppenheimer Conference - Intellectia AI
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Litchfield Hills Research Estimates ADIL FY2025 Earnings - Defense World
ADIL Technical Analysis & ETF Price Forecast - Intellectia AI
Can Adial Pharmaceuticals Inc. outperform under higher oil pricesEarnings Growth Summary & Low Risk Entry Point Tips - mfd.ru
Buyback Watch: Whats the beta of Adial Pharmaceuticals Inc stockSell Signal & Community Consensus Picks - baoquankhu1.vn
Finanzdaten der Adial Pharmaceuticals Inc-Aktie (ADIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):